NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Unknown
Clinical Trials
9 trialsNCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
NCT05420493 2024-01-05
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT05089266 2023-07-17
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
Shanghai Cell Therapy Group Co.,Ltd
Phase 1 Unknown
NCT03423992 2021-06-15
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
Xuanwu Hospital, Beijing
Phase 1 Unknown
NCT04121273 2021-03-03
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1 Unknown
NCT02186860 2021-02-10
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT03932565 2020-11-18
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors
The Sixth Affiliated Hospital of Wenzhou Medical University
Phase 1 Unknown
NCT03881774 2019-03-21
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
Phase 1 Unknown